Determining the prevalence of hepatitis Delta virus in Turkey
Find HDV and Determine Its Status in Turkey "SITU(HD)VATION"
Guven Health Group · NCT06248580
This study is trying to find out how common hepatitis Delta virus is in southeastern Turkey and how it affects patients, while also training family doctors to better diagnose and manage related infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Guven Health Group (other) |
| Locations | 2 sites (Ankara and 1 other locations) |
| Trial ID | NCT06248580 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of affected patients in southeastern Turkey. The investigators will conduct training sessions for 250 family physicians across Diyarbakir, Batman, Mardin, and Sanliurfa to enhance their ability to diagnose and manage hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and HIV infections. The study will also evaluate liver fibrosis in patients with HDV using non-invasive methods and will focus on understanding co-infections and vertical transmission rates. The ultimate goal is to contribute to the national hepatitis elimination program.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been HBsAg positive for at least six months.
Not a fit: Patients who are not HBsAg positive or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management of HDV infections, ultimately enhancing patient outcomes in Turkey.
How similar studies have performed: While this approach is focused on a specific regional prevalence assessment, similar studies in other regions have shown success in improving hepatitis management and awareness.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (Age≥18) * Being HBsAg positive for at least six months * Being a citizen of the Republic of Türkiye Exclusion Criteria: * There are no exclusion criteria in this study.
Where this trial is running
Ankara and 1 other locations
- Guven Hospital — Ankara, Turkey (Türkiye) (RECRUITING)
- Dicle University, Faculty of Medicine — Diyarbakır, Turkey (Türkiye) (RECRUITING)
Study contacts
- Principal investigator: Mustafa Kemal Çelen, MD — Dicle University, Medical Faculty, Department of Infectious Diseases
- Study coordinator: Yaşar Bayındır, MD
- Email: yasar.bayindir@guven.com.tr
- Phone: 00905323659909
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Hepatitis D Infection, Fibrosis, Liver, Hepatocellular Carcinoma, Cirrhosis, Liver, Transmission Vertical, Chronic hepatitis D, Liver Cirrhosis